Sign In
Buy TIL
$7.12
-0.0200 (-0.280%)
At Close: Jul 31, 2026
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
04:56am, Saturday, 14'th Sep 2024
Instil Bio is developing a bispecific antibody that strengthens immune responses to solid tumors by simultaneously targeting PD-L1 and VEGF. Instil Bio's lead immunology candidate is still in phase 1
Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements
01:22pm, Friday, 13'th Sep 2024
Instil Bio, Inc. in-licensing brings on board high demand IMM2510 clinical product with PD-L1/VEGF targeting of solid tumors; proof-of-concept established by Summit/Akeso and BioNTech. Two competitive
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
05:00pm, Tuesday, 13'th Aug 2024
DALLAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today anno
Q2 2024 Earnings Estimate for Precision BioSciences, Inc. (NASDAQ:DTIL) Issued By HC Wainwright
01:38am, Monday, 20'th May 2024
Precision BioSciences, Inc. (NASDAQ:DTIL – Free Report) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Precision BioSciences in a note issued to
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Friday, 10'th May 2024
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported i
What Makes Instil Bio (TIL) a New Buy Stock
01:01pm, Wednesday, 27'th Mar 2024
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
05:00pm, Thursday, 21'st Mar 2024
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported
Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why
01:32pm, Thursday, 18'th Jan 2024
Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.
Instil Bio Announces Strategic Update
08:00am, Tuesday, 16'th Jan 2024
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lympho
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
05:00pm, Tuesday, 05'th Dec 2023
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lympho
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
05:00pm, Monday, 13'th Nov 2023
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapi
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
07:00am, Monday, 06'th Nov 2023
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing
After Plunging -18.52% in 4 Weeks, Here's Why the Trend Might Reverse for Instil Bio, Inc. (TIL)
11:18am, Thursday, 31'st Aug 2023
The heavy selling pressure might have exhausted for Instil Bio, Inc. (TIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
07:00am, Monday, 14'th Aug 2023
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational i
